Carnosic acid improves diabetic nephropathy by activating Nrf2/ARE and inhibition of NF-κB pathway.
Level 5 - mechanism / opinion, no new human data
Preclinical in vitro (mouse mesangial cells) and in vivo (db/db and STZ mice) animal research without human subjects.
PubMed 30166101 · doi:10.1016/j.phymed.2018.04.031
What was done
Researchers evaluated carnosic acid (CA) in high-glucose-exposed mouse glomerular mesangial cells and in two mouse models of diabetic nephropathy: db/db mice treated for 14 weeks and streptozotocin (STZ)-induced diabetic mice treated orally for 20 weeks. Renal pathology, urinary biomarkers, signaling pathways (Nrf2 and NF-κB), and profibrotic markers (TGF-β1, fibronectin, E-cadherin) were examined, with irbesartan serving as an active comparator.
What was found
In cell culture, CA activated Nrf2 and inhibited the NF-κB pathway. In db/db mice, 14 weeks of CA reduced water intake, urine volume, and albuminuria, while increasing urine creatinine and attenuating glomerular sclerosis and mesangial expansion. In STZ-induced diabetic mice, 20 weeks of CA improved kidney damage and suppressed TGF-β1, fibronectin, and E-cadherin. Compared to irbesartan, CA demonstrated greater glucose-lowering capacity and stronger reductions in renal fibronectin and E-cadherin expression without apparent off-target tissue damage. Specific quantitative values were not reported in the abstract.
Why it matters
This study outlines potential dual antioxidant and anti-inflammatory mechanisms of carnosic acid in slowing diabetic kidney injury, offering a preclinical basis for plant-derived compounds targeting diabetic nephropathy.
Limits
The study is entirely preclinical, utilizing rodent models and cultured murine cells, which may not mirror human diabetic nephropathy. The abstract does not provide exact animal numbers, dosages, statistical confidence intervals, or quantitative effect sizes.
Cited by
- supports Carnosic acid functions as a mild Nrf2 inducer, mild NF-κB inhibitor, and mild AMPK activator.